This suggests that a therapeutically-induced inhibition of UHRF1 activity or expression could prevent the action of its preferred partners, HDAC1 and DNMT1, leading to a re-expression of the tumour suppressor genes p16INK4A and thus allowing the cancer cells to undergo apoptosis. This evidence concerns the gene CDKN2A and cancer.